|Brand name(s), other common name(s)||Arranon®|
|How the drug is given||Intravenously (IV)|
Indications and Usage
Nelarabine is FDA approved to treat people who have relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma following treatment with at least two chemotherapy regimens.
Side effects needing medical attention
Seizures; excessive sleepiness; numbness and tingling in the hands, fingers, feet or toes; problems with fine motor skills such as buttoning clothes; unsteadiness while walking; increased tripping while walking; weakness when getting out of a chair or walking up stairs; fever; signs of infection; bruising easily or unusual bleeding; difficulty breathing; fatigue; paleness.